Loading...
XSTO
QLINEA
Market cap16mUSD
, Last price  
SEK
Name

Q linea AB

Chart & Performance

D1W1MN
XSTO:QLINEA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
104.94%
Rev. gr., 5y
18.64%
Revenues
2m
-46.80%
81,0001,500,0001,066,0001,005,000243,0009,335,00012,788,0004,440,0002,362,000
Net income
-217m
L-5.45%
-60,091,000-67,879,000-128,353,000-178,060,000-220,191,000-233,183,000-275,770,000-229,366,000-216,871,000
CFO
-182m
L-20.14%
-52,834,000-62,865,000-122,712,000-169,760,000-237,305,000-255,050,000-250,863,000-228,521,000-182,495,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.
URL
https://www.qlinea.com/
IPO date
Dec 07, 2018
Employees
149
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT